Condition: Lymphoma, T-Cell · Sponsor: GC Cell Corporation
This is a Phase 1 (a and b), first in human (FIH), single-arm, open-label, multicenter study to evaluate the safety, tolerability and efficacy of GCC2005 in the treatment of patients with relapsed/refractory (R/R) NK or T-cell malignancies who have received at least two prior lines of therapy.
This description comes directly from the study's public registry record.
HyeSung Jeon · +82-31-260-9059 · hs_jeon@gccorp.com
Seungryel Han · +82-31-260-9771 · hansr@gccorp.com
Always discuss trial participation with your own doctor first.
| Seoul National University Hosptial | Seoul, Seoul, South Korea | Recruiting |
| Asan Medical Center | Seoul, Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06699771